

Anticoagulant reversal for intracranial hemorrhage (ICH) and other life threatening bleeding-update 2013*

Zumberg M, Rajasekhar A, Lawson M, Khanna A

SUMMARY TABLE-please see respective sections for further details

<u>Anticoagulant</u>	<u>Reversal</u>	<u>Comments</u>
<u>Warfarin</u>	1.)Vitamin K 10mg iv over 15-30 min and KCentra (25 u/kg if INR 1.7-4, 35 U/kg if INR 4-6, 50 U/kg if INR>6)	1.)FFP is not recommended with use of KCentra, a 4 factor nonactivated PCC, unless otherwise indicated
<u>Unfractionated heparin (UH)</u>	1.)1mg Protamine iv for each 100 units of UH 2.) infusion should not exceed 5mg/minute due to risk of anaphylaxis 3.)Maximum single dose of Protamine is 50 mg, but can be repeated	Need to consider timing and total amount of UH administered over the last 3 hours in calculation (see subsection) Increased risk of hypersensitivity reaction/anaphylaxis in patients with a fish allergy or prior protamine exposure
<u>Low molecular weight heparin(LMWH)</u>	1.)1 mg Protamine iv for each 1mg of Enoxaparin in last 8 hours 2.)1 mg Protamine iv for each	1.) Only partially reverses 2.)Note differences in dosing between Enoxaparin and other LMWHs

	<p>100 units of Dalteparin or Tinazeparin in last 8 hours</p> <p>2.)rVIIa 50-90mcg/kg iv for life threatening intractable bleed**</p>	<p>3.) 0.5 mg Protamine/1 mg lovenox (or 100 units of dalteparin) if given 8-12 hours prior</p> <p>4.)Round rVIIa dose to vial size</p>
<u>Fondaparinux (Arixtra®)</u>	<p>1.)rVIIa 90mcg/kg iv for life threatening intractable bleed** or</p> <p>2.)KCentra 50 U/kg**</p>	<p>1.)May repeat in 2 hours if bleeding recurs</p> <p>2.)Round rVIIa dose to vial size</p>
<u>Rivaroxaban</u>	<p>1.)KCentra 50 IU/kg iv**</p>	<p>1.)Novoseven 45-90 mcg/kg or FEIBA 50 U/kg can be tried if no clinical response to KCentra. Round rVIIa dose to vial size</p> <p>2.)If anti-Xa level is undetectable there is likely no anticoagulant effect and "reversal" is not necessary</p>
<u>Apixiaban</u>	<p>1.)KCentra 50 IU/kg iv**</p>	<p>1.)Novoseven 45-90 mcg/kg or FEIBA 50 U/kg can be tried if no clinical response to KCentra. Round rVIIa dose to vial size</p> <p>2.)If anti-Xa level is undetectable there is likely no anticoagulant effect and "reversal" is not necessary</p>
<u>Dabigatran</u>	<p>1.)Activated oral charcoal if ingestion within 2 hours</p> <p>2.)rVIIa 45-90 mcg/kg iv or KCentra 50 units/kg iv. Round</p>	<p>1.)Consider HD, especially if renal impairment</p> <p>2.)If thrombin time and aPTT are normal there is likely no</p>

	rVIIa dose to vial size**	anticoagulant effect and “reversal” is not necessary 3.If no clinical response to rVIIa or KCentra, FEIBA 50 U/kg can be tried
rTPA	1.)cryoprecipitate 0.1 units/kg iv if fibrinogen <100 mg/dL	1.)If bleeding is refractory or life threatening consider Aminocaproic acid (Amicar®) 1 g/10 kg iv
ECASA	1.)1 unit single donor platelet	1.)Can consider repeat 1 single donor unit if PFA-100 (orderable in EPIC) is not normalized 2.)Consider DDAVP iv or rVIIa** iv if refractory bleeding
Clpidorgrel (Plavix®)	1.)2 units of single donor platelets	1.)Consider repeating 2 units Q12 hours until the PFA-100 and Verify Now (Plavix inhibition <20% or PRU over 240) assays are normal. Both tests are orderable in EPIC 2.)Consider DDAVP iv or rVIIa** iv if refractory bleeding

* Please note these recommendations only apply to life-threatening situations where emergent reversal of anticoagulation is deemed necessary by the treating service. Most of the data comes from cases of ICH and applicability to other situations is less well studied. Adult Hematology consultation should be considered.

Examples of life threatening traumatic hemorrhage may include penetrating injury to head, neck and torso, severe blunt trauma requiring PRBC transfusion, base deficit >6, lactic acid >3, severe hypotension with SBP<90, obvious external hemorrhage from the scalp, face, neck, torso, extremities.

****Per P&T committee guidelines adult hematology consult required for approval**

Guidelines for Urgent Reversal of Warfarin related Anticoagulation in patients with Intracranial Hemorrhage or Life Threatening Bleeding

Evidence of Acute Intracranial Hemorrhage on non-contrast brain CT requiring Emergent Surgical Intervention or Associated with Neurological Instability or Decline as well as other non-ICH life-threatening bleeding where emergent reversal deemed necessary.

INR Greater than 1.7

1. Vitamin K 10 mg IV (10mg/25ml NS over 15-30 minutes)
2. KCentra 50u/kg IV over 10-15 min
3. FFP is not needed with KCentra

-KCentra is a 4 factor (II, VII, IX, X) non-activated prothrombin complex concentrate (PCC) and may carry an increased thrombogenic risk.

-KCentra and other prothrombin complex concentrates (PCCs) are contraindicated in Disseminated Intravascular Coagulation (DIC)

-Patients on warfarin usually have an underlying prothrombotic state and PCCs may exacerbate this condition.

- References:

Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. *Cleve Clin J Med*. 2013 Jul;80(7):443-51. doi: 10.3949/ccjm.80a.13025.

Lazo-Langner A, Lang ES, Douketis J. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. *Crit Care*. 2013 Jun 17;17(3):230. [Epub ahead of print]

UNC Health Care ED Anticaougluation Reversal Guidelines. Accessed August 15, 2013 at www.clotconnect.com

2011 Clinical Practice Guide on Anticoagulant Dosing and Management of Anticoagulant-Associated Bleeding Complications in Adults. Accessed August 15, 2013 at the ASH website: www.hematology.org/practiceguidelines

Stephan A. Mayer, M.D., Nikolai C. Brun, M.D., Ph.D., Kamilla Begtrup, M.Sc., Joseph Broderick, M.D., Stephen Davis, M.D., Michael N. Diringer, M.D., Brett E. Skolnick, Ph.D., and Thorsten Steiner, M.D. for the FAST Trial Investigators Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. N Engl J Med 2008; 358:2127-2137 May 15, 2008

Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three factor PCC (Profilnine) in correcting supratherapeutic INR in warfarin overdose. Transfusion. 2009; 49(6): 1171-1177

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A guideline for Healthcare Professionals From the American Heart/Stroke Association. Stroke 2010, 41:2108-2129

Proposal for Reversal of anti-Xa inhibitors

Unfractionated Heparin (UH) – half life 60-90 minutes

1.) Stop the infusion—the half life of IV heparin is only 60-90 minutes. If bleeding is not life threatening no further therapy may be necessary

2.) If further therapy is necessary **Protamine sulfate** is the treatment of choice

-infusion should not exceed 5mg/minute due to risk of bronchoconstriction,

hypotension, and anaphylaxis

-approximately 1mg of Protamine sulfate will neutralize 100-U of UH

-Maximum dose is 50 mg per 10 minutes, but may be repeated

-A higher incidence of severe allergic reaction including anaphylaxis may exist with prior Protamine exposure or exposure to Protamine containing products (ex NPH insulin) or history of fish allergy

3.) There is no role for FFP in the reversal of UH

4.) **For bleeding following a single bolus:**

Immediately following a bolus = 1mg Protamine iv/100-U UH

30 minutes to 1 hour after a bolus = 0.5 mg Protamine iv/100-U UH

2 hours or more after a bolus =0.25-0.375 mg Protamine iv/100-UH

5.)For bleeding during a Continuous infusion (CI);

Protamine (dose 1mg Protamine/ 100 U UH) should be given iv to neutralize all UH given within the last hour + one half the dose of heparin given during the proceeding hour + one-quarter of the dose of heparin given in the hour prior to that

Ex. 1000 unit UH infusion/hr

Amount of UH to neutralize is 1000U+500U+250 U=1750 units UH
Protamine dose (1mg/100 U UH) =17.5 mg iv

Low Molecular Weight Heparin-half life typically 2-8 hours depending on agent

1.)There is no proven method to fully reverse LMWH (60-80% reversal expected)

-anti-IIa activity can be neutralized

-anti-Xa activity (most of the anticoagulant effect of LMWHs) partially neutralized

2.)1mg of Protamine iv should be given for every 1mg of Enoxaparin given in the last 8 hours or for every 100 units of Dalteparin or Tinzaparin given over the last 8 hours (0.5 mg/kg should be used if last dose given between 8-12 hours prior)

3.)Recombinant VIIa (rVIIa) can be considered in the management of intractable bleeding based on case reports

- recommended dose 50-90mcg/kg iv X1 (round dose to nearest vial size). May repeat in 2 hours if bleeding recurs

Fondaparinux (Arixtra)-half life 14 hours

1.)There is no specific antidote

2.)Protamine is not effective for reversal

3.) Recombinant VIIa (rVIIa) or KCentra can be considered in the management of intractable bleeding based on case reports

- recommended dose Novosecven 90mcg/kg iv X1. May repeat every 2 hours x3 if bleeding recurs

-recommended dose of KCentra is 50 U/kg

-round dose to vial size

Rivaroxaban-half life 5-9 hours

1.)There is no specific antidote

2.)Protamine is not effective for reversal

3.)KCentra can be considered in the management of intractable bleeding -
recommended dose 50 IU/kg iv. Novoseven 45-90 mcg/kg or FEIBA 50 U/kg can be tried if no
clinical effects

-round dose to vial size

Apixiban-half- life 12 hours

1.)There is no specific antidote

2.)Protamine is not effective for reversal

3.)KCentra can be considered in the management of intractable bleeding -
recommended dose 50 IU/kg iv. Novoseven 45-90 mcg/kg or FEIBA 50 U/kg can be tried if no
clinical effects

-round dose to vial size

Oral Thrombin Inhibitor

Dabigatran-half-life 12-17 hours

1.)There is no specific antidote

2.)Dabigatran is a thrombin inhibitor, as opposed to rivaroxaban and apixiaban which are anti-Xa inhibitors

3.) Novoseven can be considered in the management of intractable bleeding -
recommended dose is 45-90 mcg/kg iv. KCentra 50 U/kg or FEIBA 50 U/kg can be tried if no
clinical effects

References

Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. *Cleve Clin J Med*. 2013 Jul;80(7):443-51. doi: 10.3949/ccjm.80a.13025.

Lazo-Langner A, Lang ES, Douketis J. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. *Crit Care*. 2013 Jun 17;17(3):230. [Epub ahead of print]

UNC Health Care ED Anticoagulation Reversal Guidelines. Accessed August 15, 2013 at www.clotconnect.com

2011 Clinical Practice Guide on Anticoagulant Dosing and Management of Anticoagulant-Associated Bleeding Complications in Adults. Accessed August 15, 2013 at the ASH website: www.hematology.org/practiceguidelines

Beshay JE, Morgan H, Madden C, Yu W, Sarode R. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. *J Neurosurg*. 2010 Feb;112(2):307-18. Review.

Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008 Jun;133(6 Suppl):141S-159S. Erratum in: *Chest*. 2008 Aug;134(2):473. PMID: 18574264

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. *Circulation*. 2011 Oct 4;124(14):1573-9. Epub 2011 Sep 6. PMID: 21900088

Tissue Plasminogen Activator (rTPA)

Guidelines for Tissue Plasminogen Activator (alteplase®) Reversal in Hemorrhagic Conversion of Ischemic Stroke as well as other life-threatening bleeding.

1. No reversal necessary two hours post tPA infusion.
2. Reversal of tPA may result in thrombosis or propagation of already infarcted tissue or thrombus.
3. Reversal only needed in symptomatic hemorrhagic conversion as evidenced by neurological decline, hemodynamic stability or other organ dysfunction.

Obtain stat CBC, PT/PTT, platelets, fibrinogen, D-dimer

If fibrinogen <100 mg/dL administer Cryoprecipitate 0.10u/kg IV

Repeat fibrinogen in 1 hour, if less than 100 mg/dL repeat Cryoprecipitate dose iv

If bleeding is life threatening or emergent neurosurgical procedure required then consider

Aminocaproic Acid (Amicar®) 1g/10kg IV in 250cc NS over 1 hour

Reversal of antiplatelet agents

Emergent Reversal of Antiplatelet Agents in the Setting of Intracranial Hemorrhage or life-threatening bleeding

Protocol:

Intracranial Hemorrhage or life-threatening bleeding & Aspirin (alone)

No baseline laboratory studies required (do not wait for labs to order platelets)

Transfuse 1 unit single donor platelets as soon as possible after diagnosis of ICH or life-threatening bleeding in a patient on aspirin monotherapy (81 or 325 mg)

Post transfusion CBC to check platelet count, and PFA-100 (platelet function assay)

Both DDAVP 0.3 ug/kg and rFVIIa 30-90 ug/kg have been suggested by some authors but we do **not** recommend these agents due to the lack of supportive evidence as well as the risks of hyponatremia (DDAVP) and high cost (rFVIIa)

Intracranial Hemorrhage or life-threatening bleeding & Clopidogrel (Plavix®) (either Clopidogrel alone or dual ASA & Clopidogrel)

No baseline laboratory studies required (do not wait for labs to order platelets)

Transfuse 2 units single donor platelets as soon as possible after diagnosis of ICH or life-threatening bleeding in a patient on Clopidogrel or dual antiplatelet therapy

Post transfusion check CBC (platelet count), PFA-100 (platelet function assay), and the Accumetrics Verify Now Assay (P2Y12 Assay) both orderable in EPIC

If Verify Now assay is abnormal (Plavix inhibition >20% or PRU under 240) after platelet transfusion, continue transfusion at a rate of 2 units single donor platelets every 12 hours until PFA-100 and Verify Now assays normalize, up to 48 hours

Both DDAVP 0.3 ug/kg and rFVIIa 30-90 ug/kg have been suggested by some authors but we do **not** recommend these agents due to the lack of supportive evidence as well as the risks of hyponatremia (DDAVP) and high cost (rFVIIa)

Discussion

Patients on antiplatelet therapy (aspirin, Clopidogrel, or both) may present with intracranial hemorrhage or life-threatening bleeding. Currently, national guidelines do not exist for the rapid reversal of these

agents, but antiplatelet therapy is associated with a significant increase in morbidity and mortality in the settings of spontaneous ICH and traumatic ICH. This document is meant to include all forms of intracranial blood products.

Both aspirin and Clopidigrel irreversibly inhibit platelet function, although through different mechanisms. Neither drug has a specific antidote. In several observational studies on intracranial hemorrhage, antiplatelet therapy was associated with an increased risk of in-hospital death and poor outcome. Additionally, some recent studies have suggested that platelet transfusion is not effective in reducing hematoma size, improving outcome, or lowering in-hospital mortality. Despite this, most expert sources continue to advise “reversal” of aspirin and Clopidigrel with platelet transfusion. Many feel that the timing of transfusion is critical, with a goal of transfusing platelets within 6 hours of the onset of hemorrhage.

Our treatment algorithm is largely based on several published reviews on the topic. The mainstay of therapy is platelet transfusion in an effort to replace the dysfunctional platelets. Alternative strategies including DDAVP and rFVIIa are not recommended due to uncertain of efficacy, risks of hyponatremia, and high cost.

Recent studies in the cardiovascular surgery literature suggest that the new Accumetrics Verify Now assay of Plavix-induced platelet inhibition can “clear” patients for surgery. Previously, cardiac patients on aspirin and Plavix had to wait 7 days after cessation of both agents prior to open cardiac surgery, due to the bleeding complications. However, guidelines now state that individuals who have stopped Plavix and have a normal Verify Now assay may proceed to surgery, without waiting the full 7 days. We feel that this assay may be useful in determining if continued platelet transfusion is needed, as some authors have suggested.¹⁻⁷

References

1. Beshay JE, Morgan H, Madden C, Yu W, Sarode R. Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients. *J Neurosurg.* Feb;112(2):307-318.
2. Campbell PG, Sen A, Yadla S, Jabbour P, Jallo J. Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: a clinical review. *World Neurosurg.* Aug-Sep;74(2-3):279-285.
3. Creutzfeldt CJ, Weinstein JR, Longstreth WT, Jr., Becker KJ, McPharlin TO, Tirschwell DL. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. *J Stroke Cerebrovasc Dis.* May-Jun 2009;18(3):221-228.
4. Ducruet AF, Hickman ZL, Zacharia BE, et al. Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. *Neurol Res.* Sep;32(7):706-710.
5. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. *The Annals of Thoracic Surgery.* 91(3):944-982.
6. Naidech AM, Bernstein RA, Lavesseur K, et al. Platelet activity and outcome after intracerebral hemorrhage. *Ann Neurol.* Mar 2009;65(3):352-356.

7. Naidech AM, Jovanovic B, Liebling S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. *Stroke*. Jul 2009;40(7):2398-2401.